Santo Therapeutics Ltd is a pioneering biotechnology company focused on developing innovative gene therapies for cancer and rare genetic disorders. Through its proprietary platform, Santo is committed to delivering safe, effective, and accessible gene-based treatments to patients worldwide.

The company’s robust pipeline includes six first-in-class therapeutic candidates targeting conditions such as bladder cancer, neurofibromatosis, malignant pleural mesothelioma, and glioblastoma. By driving scientific innovation and advancing breakthrough technologies, Santo aims to transform cancer care and improve outcomes for patients around the globe.